1 insider bought €136k of shares over the last 90 days, the latest by Johan Kallblad, filed 28 Aug 2026.
Analysts rate Carasent AB (publ) Strong Buy (bullish), based on 2 analysts. Average price target: SEK 34.93.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 30 declarations
The 17 filings of Carasent AB (publ), a Swedish health care company listed in Stockholm, revolve around one board member: Johan Kallblad, Styrelseledamot, bought EUR 58,654 on August 27, 2026, EUR 54,133 on August 26, 2026 and EUR 43,373 on May 28, 2026, and sold EUR 21,282 on that same May 28. In all, 8 purchases weigh EUR 229,649, with a median of EUR 23,986, against 2 sales worth EUR 145,402, or 80% purchases among open-market trades.
The largest sale, EUR 124,120, is Daniel Öhman's, Verkställande direktör (VD), on October 20, 2025. Between May 12, 2026 and May 28, 2026, two insiders bought EUR 46,408 in all. Henric Carlsson, Styrelseledamot, and Stefan Jernberg have one purchase each, and 7 filings are neither purchases nor sales.
Activity rises, from 6 filings in 2024 to 8 in 2026, and the last twelve months hold 9, of which 7 purchases and one sale. The 10 filers hold 19% of the capital, valued at SEK 1.8 billion, and filings appear on the day of the trade, as a median.
Purchases our model currently ranks for the recommendations list.
All recommendations